What we actually see repeatedly across the pharmaceutical sites we audit and rebuild in European markets, not a market research report, a working practitioner’s view.
Across the multi-market pharmaceutical websites we work on and audit, the same patterns keep resurfacing regardless of company size or geography. This piece pulls together what we consistently observe: where digital estates tend to fragment, which technical foundations — multilingual targeting, accessibility, consent — most often fail in practice, and where platform choice and AI visibility are quietly shifting. It also sets out the gap that has opened between large pharmaceutical groups and the mid-size and affiliate sites operating under the same regulatory pressure with far less internal capacity, and what we would look at first if asked to audit a typical mid-size site today.
The observations in this article are drawn from ongoing client and market research work carried out over the course of 2025–2026. This is not a formal, representative market study or a statistically sampled survey: it reflects what we have repeatedly encountered during real project work — audits, migrations and competitive research — primarily on corporate, product and affiliate sites for pharmaceutical companies operating in European markets. The sites referenced were reviewed in the ordinary course of that work rather than selected through any structured sampling method, and the patterns described here are the ones that have recurred often enough, across enough of those sites, to be worth naming. Where we describe something as common or typical, we mean common or typical in what we have personally reviewed, not a claim about the market as a whole.
Most multi-market European pharmaceutical groups we encounter have more digital properties than anyone internally can fully account for: a corporate site, several product sites, an old campaign microsite still technically live, and affiliate sites built independently by different teams over different years. The default trajectory, left unmanaged, is accumulation, not consolidation. Each site was usually reasonable on its own terms when it was commissioned — a product launch needed a microsite, a new affiliate needed a local presence — but no owner had been assigned to manage the resulting collection as a whole. The result is a digital estate that grows by addition and almost never by subtraction, so old properties keep serving traffic, keep collecting data, and keep carrying whatever compliance debt they had on the day they were built.
Three technical areas account for most of what surfaces during an audit, and they tend to fail independently of each other — a site can get one right while badly missing the other two.
Incorrect or entirely missing hreflang implementation is the single most common technical finding across the multi-market sites we audit, and correcting it is consistently one of the highest-impact fixes available — see hreflang for pharma websites. The pattern is rarely a total absence of multilingual setup; it is usually a partial one, built for an early phase of the site and never revisited as markets were added or removed. Search engines then have no reliable signal for which version of a page to show in which market, so traffic gets misrouted, duplicate-content issues appear, and local teams lose confidence in metrics that no longer reflect what visitors are actually seeing.
Contrast failures on brand colours never checked against the actual palette, untagged PDF documents assumed compliant because the surrounding site passes an automated scan, and inaccessible third-party widgets embedded for booking or store-locator functionality. These three account for a large share of what we find during audits, consistently. What links them is that each one sits just outside the boundary of a standard automated scan: brand colour is treated as a design decision rather than a compliance variable, PDFs are treated as static assets rather than content that needs the same conformance work as the page hosting them, and third-party widgets are treated as someone else’s responsibility because the code wasn’t written in-house.
A consent banner exists on nearly every site we review; whether the tracking behind it actually respects a declined choice is a different and far less consistently answered question, particularly with third-party embeds that continue collecting regardless of the visitor’s decision. The banner itself is rarely the problem — it is usually implemented competently and looks correct in a quick manual check. The gap shows up underneath it, in scripts that were wired up once and never reconnected to the consent layer as new tools were added, so a visitor who declines tracking may still be tracked by whatever was bolted on most recently.
Large groups with corporate-level digital mandates often run legacy AEM or Sitecore instances, sometimes years past when the decision still made sense for their current team size. A growing share of mid-size and independent companies choose a properly structured WordPress build instead, for cost and operability reasons rather than a change in what the platform can technically do. The choice tends to track team size and in-house capacity more closely than it tracks company revenue: a large group with a lean regional digital team can be just as constrained by an enterprise CMS as a mid-size company would be, while a smaller company with a properly resourced WordPress build can out-perform a much larger competitor on the things that are actually visible to a visitor — speed, accessibility, and how current the content is.
Awareness of AI search visibility as a genuine consideration, rather than a speculative future concern, has grown noticeably, and more companies are proactively auditing their AI representation before being prompted by a competitive gap — a rare instance of the sector getting ahead of a trend rather than reacting to it. It is a useful counterpoint to the rest of this piece: most of what we describe here is a backlog of unresolved problems, but this particular shift shows the sector is capable of moving early on something when the incentive is clear enough, rather than waiting for a regulatory deadline to force the issue.
Large pharmaceutical companies have generally solved the basics — accessible, reasonably fast, properly multilingual sites — while mid-size and affiliate sites lag noticeably, often years behind on accessibility conformance and technical SEO fundamentals specifically because they carry the same regulatory complexity as a large company without a comparable internal team. That gap is closing under EAA pressure, but slower than the deadline assumes for a meaningful share of the market. The underlying issue is capacity rather than awareness: most of these teams already know their site has accessibility or multilingual gaps, but resolving them competes against local marketing priorities with a much smaller budget and no dedicated digital owner, so fixes happen only when a deadline or an external audit forces prioritisation.
In the sites we review, the most common gaps cluster around three things.
None of these are unusual or specific to one company — they are the same three findings we would expect to surface on most mid-size pharmaceutical sites we have not yet looked at, which is exactly why they are worth checking first.
No — it reflects patterns repeatedly encountered across ongoing client audit, migration and competitive research work carried out through 2025 and 2026, not a commissioned or statistically sampled industry survey. Where something is described as common or typical, that means common in what has been directly reviewed, not a claim about the market as a whole, so it should be read as informed observation rather than a representative study.
Incorrect or entirely missing hreflang targeting on multilingual sites, usually a partial setup built for an early phase of the site and never revisited as markets were added or removed. Search engines then have no reliable signal for which version to show which market, so traffic gets misrouted and duplicate-content issues appear. See hreflang for pharma websites for the fix.
Run a structured audit rather than a quick manual look, covering hreflang and canonical targeting, accessibility tested with real assistive technology rather than an automated scan alone, and whether consent choices are respected by every script on the site, not only the banner. See how to audit a pharma website for the practical sequence, since these three areas are where most sites carry gaps an automated check alone would miss.
It reflects patterns from sites directly audited and worked on rather than a formal, published study, so treat the observations here as informed field experience rather than a statistically representative survey. The value is in the recurring patterns themselves — hreflang, accessibility and consent gaps that show up across company sizes and geographies — which is worth checking against your own site directly rather than assuming the pattern does not apply to you.
Tell us what you have and we will audit it against what we actually see across the sector.